cardiovascular complication News
-
Major Biomedical Catalyst grant win
£1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of ...
-
Solvay Ventures invests in Invizius
Solvay Ventures announces today its equity investment in Invizius, the University of Edinburgh spin-out developing potentially lifesaving products that reduce complications rates suffered by dialysis patients. Solvay Ventures invests alongside Mercia Asset Management, Downing Ventures, the University of Edinburgh’s Old College Capital fund and the Scottish Investment Bank. Invizius is ...
-
Invizius announces £5.3m Series A
£5.3 million financing to complete First-in-Man safety study Led by Mercia, Downing Ventures, Old College Capital, Scottish Enterprise and Solvay Ventures; welcomes new investors Calculus Capital and Dr Jonathan Milner Invizius, a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of ...
-
Invizius attracts £2.75m Pre-Series A investment
Invizius, the University of Edinburgh spin-out whose technology could help reduce the high death rates amongst dialysis patients, has raised £2.75m from a consortium of investors. The funding round was led by Mercia and included Downing Ventures, the University’s Old College Capital fund and the Scottish Investment Bank. The latest investment will support the company as it conducts ...
-
BioStable Science & Engineering Announces CE Mark Approval for the HAART 200 Aortic Annuloplasty Device & Surpasses 1,000 Patients Treated Worldwide with the HAART Devices
BioStable Science & Engineering, Inc., (“BioStable”) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair. With CE Mark approval of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable will be able to offer surgeons within the European Union a comprehensive portfolio of ...
-
Invizius secures £0.5m investment
A spinout company whose technology could save the lives of thousands of dialysis patients has secured £500,000 from Mercia Asset Management, in the first investment deal since Mercia’s partnership with the University of Edinburgh was announced in November 2017. Invizius stems from years of research by Invizius co-founder, Dr Andy Herbert and his team, who believe they have ...
-
Impact of antidiabetic treatments must be taken into account in studying the gut microbiota
Research on gut microbiota (bacteria of the digestive tract) has for some years greatly contributed to advancing medical science. Within an international consortium, INRA scientists along with foreign colleagues have shown the impact of the antidiabetic treatment metformin on the gut microbiota of Type 2 Diabetes patients (T2D). The results, published in Nature on December 2, stress that the ...
-
Drug developed by Galveston scientist to be tested for COVID-19 use
A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems related to COVID-19, thanks to a $1.5 million grant from the federal government to be released June 1. Chrysalin, or TP508, a regenerative thrombin peptide developed by scientist Darrell Carney, has been tested in human clinical trials for skin and bone tissue repair ...
-
BIOMODEX Technology Enables New Milestone in Interventional Cardiology
BIOMODEX, the leader in bio-realistic haptic simulators for patient-specific rehearsal and physician training, today announced that its LAACS (Left Atrial Appendage Closure System) solution was used to perform a simulation ahead of a live case to be presented at the TVT Structural Heart Summit in Miami, FL. Physicians at the Montreal Heart Institute in Montreal, Quebec recently rehearsed the ...
By BIOMODEX
-
Tissue Genesis, LLC Provides Cell Isolation Processing for Patients with Critical Limb Ischemia (CLI) in Ukrainian Clinical Study
Tissue Genesis, LLC, the leading provider of cell isolation technology is pleased to announce that the Icellator® is being used to generate therapeutic cell preparations at the V.P. Komisarenko Institute of Endocrinology and Metabolism in Kiev, Ukraine, for patients with critical limb ischemia (CLI). The autologous stem-cell therapy, which utilizes a patient’s own fat cells, is the ...
-
Second grant win to research Peritoneal Dialysis indication
Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard technology. Globally there are 3.5 million patients who are ...
-
Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study FIGARO-DKD included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD ...
By Bayer AG
-
Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the ...
By Bayer AG
-
Kerendia (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study
U.S. Food and Drug Administration (FDA) granted label update for Kerendia (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) FIGARO-DKD investigated the efficacy and safety of finerenone versus placebo in addition to standard of care on the reduction of CV ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you